Phentermine and topiramate extended-release: A new treatment for obesity and its role in a complications-centric approach to obesity medical management

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 741-756

  Garvey, William Timothy ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cardiometabolic disease; Metabolic syndrome; Obesity; Phentermine and topiramate extended release; Prediabetes; Sleep apnea; Type 2 diabetes; Weight loss

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; BENZPHETAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LORCASERIN; MOXIFLOXACIN; NALTREXONE; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

APPETITE; AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BARIATRIC SURGERY; BEHAVIOR CHANGE; BLURRED VISION; BODY WEIGHT; BRONCHITIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; COMORBIDITY; CONSTIPATION; COUGHING; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSLIPIDEMIA; FAT INTAKE; FATIGUE; GASTROENTERITIS; HEART REPOLARIZATION; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID ABSORPTION; LONG TERM CARE; LOW CALORY DIET; MAXIMUM PLASMA CONCENTRATION; MEDICAL CARE; MIGRAINE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SINUSITIS; SLEEP DISORDERED BREATHING; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; WOUND HEALING; XEROSTOMIA;

ANTI-OBESITY AGENTS; DELAYED-ACTION PREPARATIONS; FRUCTOSE; HUMANS; OBESITY; OVERWEIGHT; PHENTERMINE; WEIGHT LOSS;

EID: 84882994306     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.806481     Document Type: Review

References (51)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307(5):491-7
2. Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obesity Rev 2001;2(4):219-29
3. National Heart, Lung, and Blood Institute. The clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health, Bethesda; 1998;NIH Publication No. 98-4083
4. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110(18):2952-67
5. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1):S11-66
6. Reaven GM. Importance of identifying the overweight patient who will benefit the most by losing weight. Ann Intern Med 2003;138(5):420-3
7. Schmier JK, Jones ML, Halpern MT. Cost of obesity in the workplace. Scand J Work Environ Health 2006;32(1):5-11
8. Belviq [package insert]. Arena Pharmaceuticals, Zofingen, Switzerland
9. Qsymia [package insert]. VIVUS, Inc., Mountain View, CA
10. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307(1):56-65
11. Bal BS, Finelli FC, Shope TR, Koch TR. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol 2012;8(9):544-56
12. Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10(7):653-62
13. Keidar A. Bariatric surgery for type 2 diabetes reversal: the risks. Diabetes Care 2011;34(Suppl 2):S361-6
14. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation 2012;125(13):1695-703
15. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61
16. James WP, Caterson ID, Coutinho W, et al. SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363(10):905-17
17. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56
18. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96(10):3067-77
19. Makowski CT, Gwinn KM, Hurren KM. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obesity Facts 2011;4(6):489-94
20. Rueger R, Garvey WT, Morelos S, Troupin B. Glycemic improvement and weight loss with low-dose, controlled-release phentermine/topiramate. Abstract 181580. American Association of Diabetes Educators 37th Annual Meeting (AADE); 4 - 7 August 2010; San Antonio, Texas, USA
21. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012;35(11):1529-39
22. Chowdhuri S. Continuous positive airway pressure for the treatment of sleep apnea. Otolaryngol Clin North Am 2007;40(4):807-27
23. Brownell K. The LEARN program for weight management. The Life Style Co, Dallas; 2000
24. Jordan J, Astrup A, Day WW. Effects of phentermine and extended-release topiramate alone and in combination on cardiovascular risk factors. Poster 697. 48th Annual Meeting of the European Association for the Study of Diabetes; 1 - 5 October 2012; Berlin, Germany
25. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012;20(2):330-42
26. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9774):1341-52
27. Garvey WT, Peterson CA, Troupin B. Weight loss with low-dose, controlled-release phentermine/topiramate therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus [abstract T5: P102]. 18th European Congress of Obesity; 25 - 28 May 2011; Istanbul, Turkey
28. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308
29. United States FDA. Slides for the February 22, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. http://www.fda. gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugs AdvisoryCommittee/ucm293903.htm [Last accessed 8 January 2013]
30. Green MW, Seeger JD, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. Headache 2012;52(7):1070-84
31. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocrine Pract 2012;18(5):642-8
32. Hofso D, Jenssen T, Bollerslev J, et al. Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2011;164(2):231-8
33. Look AHEAD Research Group. Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30(6):1374-83
34. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170(17):1566-75
35. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353(20):2111-20
36. Davidson MH, Tonstad S, Oparil S, et al. Changes in cardiovascular risk associated with phentermine and topiramate extended release in participants with comorbidities and a body mass index 27 kg/m2. Am J Cardiol 2013;published on-line January 29, 2013; doi: 10.1016/j. amjcard.2012.12.038
37. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640-5
38. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1):S67-74
39. Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004;27(4):978-83
40. Bluher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 2012;19(5):341-6
41. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008;168(15):1617-24
42. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004;109(6):706-13
43. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366(9497):1640-9
44. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31(3):596-615
45. Benotti PN, Still CD, Wood GC, et al. Preoperative weight loss before bariatric surgery. Arch Surg 2009;144(12):1150-5
46. Heber D, Greenway FL, Kaplan LM, et al. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95(11):4823-43
47. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007;66(4):433-9
48. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005;90(12):6364-9
49. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51(1):121-9
50. Tuomilehto HP, Seppa JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009;179(4):320-7
51. Church T, Troupin B. Improvements in quality of life by magnitude of weight loss in obese and overweight subjects. Abstract 1623811. 36th Annual Society of General Internal Medicine; 24 - 27 April 2013; Denver, Colorado